1,589
Participants
Start Date
January 31, 2020
Primary Completion Date
November 30, 2022
Study Completion Date
June 30, 2023
Strategy 2: Symptom screen, Genexpert and TST
Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
Strategy 3:Symptom screen, CXR but NO TST
Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
Centre National Hospitalier Universitaire de Pneumo Phtisiologie de Cotonou (CNHU-PPC), Cotonou
Manaus, Manaus
Porto Alegre, Porto Alegre
Centro de Estudos, Pesquisa e Desenvolvimento Tecnológico em Saúde Coletiva - CEPESC, Rio de Janeiro
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER